CPT-Pharmacometrics & Systems Pharmacology

Papers
(The H4-Index of CPT-Pharmacometrics & Systems Pharmacology is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Scientific and regulatory evaluation of mechanistic in silico drug and disease models in drug development: Building model credibility59
Physiologically‐based pharmacokinetic modeling to support bioequivalence and approval of generic products: A case for diclofenac sodium topical gel, 1%42
An artificial neural network−pharmacokinetic model and its interpretation using Shapley additive explanations40
Quantitative systems pharmacology: Landscape analysis of regulatory submissions to the US Food and Drug Administration30
PK/PD modeling of FXI antisense oligonucleotides to bridge the dose‐FXI activity relation from healthy volunteers to end‐stage renal disease patients30
A novel method based on unbiased correlations tests for covariate selection in nonlinear mixed effects models: The COSSAC approach30
Increasing application of pediatric physiologically based pharmacokinetic models across academic and industry organizations30
Prediction of drug concentrations in milk during breastfeeding, integrating predictive algorithms within a physiologically‐based pharmacokinetic model29
Quantitative prediction of breast cancer resistant protein mediated drug‐drug interactions using physiologically‐based pharmacokinetic modeling27
Approaches to handling missing or “problematic” pharmacology data: Pharmacokinetics27
A hybrid machine learning/pharmacokinetic approach outperforms maximum a posteriori Bayesian estimation by selectively flattening model priors25
Guide to development of compound files for PBPK modeling in the Simcyp population‐based simulator25
Bench‐to‐bedside translation of chimeric antigen receptor (CAR) T cells using a multiscale systems pharmacokinetic‐pharmacodynamic model: A case study with anti‐BCMA CAR‐T24
Reinforcement learning and Bayesian data assimilation for model‐informed precision dosing in oncology23
Opportunities and challenges for applying model‐informed drug development approaches to gene therapies23
Translational pharmacokinetic‐pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose22
Perspective on model‐informed drug development22
A mechanism‐based pharmacokinetic model of remdesivir leveraging interspecies scaling to simulate COVID‐19 treatment in humans22
Heterogeneous treatment effect analysis based on machine‐learning methodology21
PBPK modeling to predict drug‐drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction21
PBPK Model of Coproporphyrin I: Evaluation of the Impact of SLCO1B1 Genotype, Ethnicity, and Sex on its Inter‐Individual Variability21
0.12162899971008